share_log

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

Intelligent Bio Solutions | 8-K：Intelligent Bio Solutions Inc. 公布2024财年第四季度和全年财务业绩和运营亮点
美股SEC公告 ·  2024/09/19 16:20

Moomoo AI 已提取核心信息

Intelligent Bio Solutions achieved significant growth in FY2024, with revenue increasing 148% to $3.11M and Q4 revenue rising 64% YoY to $0.73M. The company reported a 20% increase in cartridge sales and 26% growth in reader sales, serving over 400 active business customers with more than 1,000 readers installed. Cash position stood at $6.30M as of June 30, 2024.The company made substantial operational progress, completing the in-clinic portion of its Pharmacokinetic study for FDA 510(k) clearance, securing a new European patent for its DSR-Plus Cartridge Reader, and expanding into new markets including New Zealand and Chile. The company also maintained ISO 13485:2016 certification and advanced development of new drug testing capabilities for ketamine and tramadol.Operating loss improved to $10.28M from $12.59M in the previous year, driven by revenue growth and reduced operating expenses. The company remains focused on strategic geographical expansion and is on track for planned FDA 510(k) submission in Q4 2024, positioning for further growth opportunities in 2025.
Intelligent Bio Solutions achieved significant growth in FY2024, with revenue increasing 148% to $3.11M and Q4 revenue rising 64% YoY to $0.73M. The company reported a 20% increase in cartridge sales and 26% growth in reader sales, serving over 400 active business customers with more than 1,000 readers installed. Cash position stood at $6.30M as of June 30, 2024.The company made substantial operational progress, completing the in-clinic portion of its Pharmacokinetic study for FDA 510(k) clearance, securing a new European patent for its DSR-Plus Cartridge Reader, and expanding into new markets including New Zealand and Chile. The company also maintained ISO 13485:2016 certification and advanced development of new drug testing capabilities for ketamine and tramadol.Operating loss improved to $10.28M from $12.59M in the previous year, driven by revenue growth and reduced operating expenses. The company remains focused on strategic geographical expansion and is on track for planned FDA 510(k) submission in Q4 2024, positioning for further growth opportunities in 2025.
智能生物解决方案在2024财年实现了显著增长，营业收入增加了148%，达311万美元，第四季度营业收入同比增长64%，达到73万美元。公司报告称，卡尺销售增长20%，读者销售增长26%，为超过400家活跃的业务客户提供服务，安装了超过1,000台读者。截至2024年6月30日，现金储备为630万美元。公司在运营方面取得了重大进展，完成了FDA 510(k)批准的药物动力学研究在诊所部分，获得了DSR-Plus卡尺读取器的新欧盟专利，并扩展到包括新西兰和智利在内的新市场。公司还维持了ISO 13485:2016认证，并推进了新药物检测能力的开发，涵盖氟西汀和曲马多。营业损失改善至1028万美元，较前一年的1259万美元有所减少，这得益于营业收入的增长和营业费用的减少。公司仍专注于战略地理扩张，并计划在2024年第四季度提交FDA 510(k)申请，为2025年进一步增长机会做好准备。
智能生物解决方案在2024财年实现了显著增长，营业收入增加了148%，达311万美元，第四季度营业收入同比增长64%，达到73万美元。公司报告称，卡尺销售增长20%，读者销售增长26%，为超过400家活跃的业务客户提供服务，安装了超过1,000台读者。截至2024年6月30日，现金储备为630万美元。公司在运营方面取得了重大进展，完成了FDA 510(k)批准的药物动力学研究在诊所部分，获得了DSR-Plus卡尺读取器的新欧盟专利，并扩展到包括新西兰和智利在内的新市场。公司还维持了ISO 13485:2016认证，并推进了新药物检测能力的开发，涵盖氟西汀和曲马多。营业损失改善至1028万美元，较前一年的1259万美元有所减少，这得益于营业收入的增长和营业费用的减少。公司仍专注于战略地理扩张，并计划在2024年第四季度提交FDA 510(k)申请，为2025年进一步增长机会做好准备。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    美联储暂停降息，你如何调整持仓？
    美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？ 展开
    联邦公开市场委员会新闻发布会，2025年1月29日